BPC-157 vs Sermorelin

BPC-157 is believed to accelerate angiogenesis and upregulate growth hormone receptors locally at injury sites. It appears to promote fibroblast migration and collagen synthesis, contributing to faster tissue remodelling. Animal studies suggest systemic effects via modulation of the dopaminergic and serotonergic systems, though human data remain limited.

BPC-157 is a synthetic pentadecapeptide derived from a protective protein found in human gastric juice. It is commonly researched for its role in soft tissue repair, particularly in tendons, ligaments, and muscle following injury or high training loads. Early research suggests it may also support gut integrity and systemic healing.

Sermorelin is a synthetic analogue of the first 29 amino acids of endogenous growth hormone-releasing hormone (GHRH). It binds to GHRH receptors on pituitary somatotrophs, stimulating pulsatile GH secretion in a physiological pattern that preserves the natural hypothalamic-pituitary feedback axis — contrasting with direct GH administration. Downstream IGF-1 elevation mediates many of its body composition, tissue-repair, and sleep quality effects.

Sermorelin is a GHRH analogue used to stimulate endogenous growth hormone production. It is one of the most widely prescribed peptides in the anti-aging and functional medicine space, valued for preserving the natural pituitary feedback axis while supporting body composition, sleep quality, and tissue repair. Compounded formulations are available in the US through 503A pharmacies.